A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients With Previously Treated Intermediate and High Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma
OBJECTIVES:
I. Determine the objective response rate to flavopiridol by patients with previously treated
intermediate and high grade non-Hodgkin's lymphoma and mantle cell lymphoma.
II. Determine the toxicity of flavopiridol administered as a continuous infusion every 2
weeks in these patients.
III. Study the pharmacokinetics of flavopiridol in these patients.
OUTLINE: This is an open label, multi-institutional study.
Patients receive treatment on an outpatient basis. Flavopiridol is administered as a
continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of
therapy unless unacceptable toxicity or disease progression occurs. Patients are followed
until death.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Todd M. Zimmerman, MD
Study Chair
University of Chicago
United States: Food and Drug Administration
NCI-2012-02253
NCT00003039
September 1997
Name | Location |
---|---|
University of Chicago Cancer Research Center | Chicago, Illinois 60637 |
Evanston Northwestern Health Care | Evanston, Illinois 60201 |
Lutheran General Hospital | Park Ridge, Illinois 60068 |
Louis A. Weiss Memorial Hospital | Chicago, Illinois 60640 |
Clinical Sciences Building | Chicago, Illinois 60612 |
Cancer Care Specialists of Central Illinois, S.C. | Decatur, Illinois 62526 |
Oncology/Hematology Associates of Central Illinois, P.C. | Peoria, Illinois 61602 |
Central Illinois Hematology Oncology Center | Springfield, Illinois 62701 |
Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne, Indiana 46885-5099 |
Michiana Hematology/Oncology P.C. | South Bend, Indiana 46617 |